There’s another pipeline we need to talk about
One of the major stumbling blocks for many promising ventures is that fork in the road where more money is needed to reach clinical validation, but funding is scarce for early growth capital.
There’s only one word running through my mind these days: pipeline. I’m not referring to Kinder Morgan, oil development or Canada’s latest acquisition.
SPONSORED CONTENT
Get Tuesdays: Innovation & Industry Newsletter
The policies, decisions, and people working on investment and regulation in the industry and innovation realm.
By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy
